Data gathered: April 26
AI Stock Analysis - BridgeBio Pharma (BBIO)
Analysis generated January 3, 2025. Powered by Chat GPT.
BridgeBio Pharma is a biotechnology company that focuses on developing medicines for genetic diseases. The company identifies, releases, and commercializes promising drug candidates. It operates with a strong emphasis on precision medicine to treat rare genetic diseases. Over recent years, BridgeBio Pharma has continued to expand its pipeline of therapies and collaborates with various institutes to ensure a constant flow of innovative treatments to the market.
Stock Alerts - BridgeBio Pharma (BBIO)
 |
BridgeBio Pharma | April 25 Insider Alert: Kumar Neil is selling shares |
|
BridgeBio Pharma | April 17 Insider Alert: Ellis Andrea is continuing selling shares |
|
BridgeBio Pharma | April 10 Price is down by -5.1% in the last 24h. |
|
BridgeBio Pharma | April 9 Price is down by -5.7% in the last 24h. |
Alternative Data for BridgeBio Pharma
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 21 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 44,000 | Sign up | Sign up | Sign up |
| Employee Rating | 86 | Sign up | Sign up | Sign up |
| Google Trends | 5 | Sign up | Sign up | Sign up |
| Patents | 43 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 10 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,101 | Sign up | Sign up | Sign up |
| Twitter Mentions | 26 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 28 | Sign up | Sign up | Sign up |
| Business Outlook | 89 | Sign up | Sign up | Sign up |
| Linkedin Employees | 715 | Sign up | Sign up | Sign up |
About BridgeBio Pharma
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development.
| Price | $36.31 |
| Target Price | Sign up |
| Volume | 1,290,000 |
| Market Cap | $6.9B |
| Year Range | $22.35 - $37.59 |
| Dividend Yield | 0% |
| Analyst Rating | 88% buy |
| Earnings Date | April 29 '25 |
| Industry | Biotechnology |
In the news
BridgeBio Pharma : BBIO – Canavan GTx BBP-812 – NTSAD 2025 – CANaspire Program UpdatesApril 25 - Finnhub |
|
Hedgehog Pathway Inhibitors Market Report 2025: Analysis and Forecast (2020-2030) by Generic Drug, Dosage, End User, Region and Company - Featuring BridgeBio Pharma, Eli Lilly, Roche & MoreApril 25 - GlobeNewswire |
|
 |
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Legal & General Group PlcApril 23 - ETF Daily News |
Purcell & Lefkowitz LLP Announces Shareholder Investigation of BridgeBio Pharma, Inc. (NASDAQ: BBIO)April 22 - Finnhub |
|
|
Leerink Partnrs Has Positive Outlook for BBIO Q1 EarningsApril 19 - ETF Daily News |
|
Brokerages Set BridgeBio Pharma, Inc. (NASDAQ:BBIO) PT at $53.00April 18 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 5.9M | 2.1M | 3.8M | -265M | -235M | -1.374 |
| Q3 '24 | 2.7M | 600,000 | 2.1M | -162M | -140M | -0.860 |
| Q2 '24 | 2.2M | 600,000 | 1.6M | -73M | -51M | -0.390 |
| Q1 '24 | 211M | 1.9M | 209M | -35M | -11M | -0.200 |
| Q4 '23 | 1.7M | 600,000 | 1.1M | -168M | -148M | -0.960 |
Insider Transactions View All
| Kumar Neil filed to sell 4,873,447 shares at $34.1. April 24 '25 |
| Ellis Andrea filed to sell 12,000 shares at $35. April 16 '25 |
| Ellis Andrea filed to sell 12,000 shares at $34.1. April 3 '25 |
| Kumar Neil filed to sell 4,948,447 shares at $36.9. March 27 '25 |
| Valantine Hannah filed to sell 1,764 shares at $32.6. March 10 '25 |
Similar companies
Read more about BridgeBio Pharma (BBIO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of BridgeBio Pharma?
The Market Cap of BridgeBio Pharma is $6.9B.
When does BridgeBio Pharma report earnings?
BridgeBio Pharma will report its next earnings on April 29 '25.
What is the current stock price of BridgeBio Pharma?
Currently, the price of one share of BridgeBio Pharma stock is $36.31.
How can I analyze the BBIO stock price chart for investment decisions?
The BBIO stock price chart above provides a comprehensive visual representation of BridgeBio Pharma's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling BridgeBio Pharma shares. Our platform offers an up-to-date BBIO stock price chart, along with technical data analysis and alternative data insights.
Does BBIO offer dividends to its shareholders?
As of our latest update, BridgeBio Pharma (BBIO) does not offer dividends to its shareholders. Investors interested in BridgeBio Pharma should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of BridgeBio Pharma?
Some of the similar stocks of BridgeBio Pharma are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.